Skip to main content
SpringerLink
Log in

Neuroendokrine Tumoren

  • Chapter
PET/CT-Atlas

  • 3828 Accesses

Zusammenfassung

Neuroendokrine Tumoren (NET) werden klinisch in funktionelle und nichtfunktionelle Tumoren unterschieden. Hochdifferenzierte Tumoren stellen die überwiegende Mehrzahl der NET (90 %) dar. Diese zeichnen sich durch einen hohen Besatz an Somatostatinrezeptorsubtypen aus und sind entsprechend mit der Somatostatinrezeptorszintigraphie (Octreoscan) und der PET/CT darstellbar. Letztere ist in Bezug auf eine höhere Sensitivität und der häufigeren Detektion von Metastasen der Szintigraphie überlegen. Bei funktionellen pankreatischen Tumoren ist die PET/CT-Diagnostik (mit 68Ga-DOTATOC oder 18F-DOPA) oft therapieentscheidend, da für eine kurative Resektion die exakte Lokalisation essenziell ist. Nichtkurativ resektable NET werden mittels antisekretorischer und antiproliferativer Ansätze therapiert. Je nach Vorkommen und Stadium werden auch die Somatostatinrezeptor-vermittelte Radiorezeptortherapie (PPPR) und lokoregionale Verfahren angewandt. Bei Auswahl der PRRT leistet die PET/CT einen wertvollen Beitrag.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  1. Modlin IM, Lye KD, Kidd M (2003) A 5-decade analysis of 13 715 carcinoid tumors. Cancer 97: 934–959

    Article  PubMed  Google Scholar 

  2. Yao JC, Hassan M et al. (2008) One hundred years after »carcinoid «: Epidemiology of and prognostic factors for neuroendocrine tumors in 35 825 cases in the United States. J Clin Oncol 26(18): 3063–3072

    Article  PubMed  Google Scholar 

  3. Rindi G, Kloppel G, Ahlmann H et al. (2006) TNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system. Virchows Arch 449(4): 395–401

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Modlin IM, Gustafsson BI, Moss SF, Pavel M et al. (2010) Chromogranin A: Biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 17: 2427–2443

    Article  PubMed  Google Scholar 

  5. Gabriel M, Decristoforo C, Kendler D et al. (2007) 68 Ga-DOTATyr3- octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48: 508–18

    Article  CAS  PubMed  Google Scholar 

  6. Kann PH, Balakina E, Ivan D et al. (2006) Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: An endoscopic ultrasound imaging study. Endocr Relat Cancer 13(4): 1195–1202

    Article  CAS  PubMed  Google Scholar 

  7. Sundin A, Vullierme MP, Kaltsas G et al. (2009) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological examinations. Neuroendocrinology 90(2): 167–183

    Article  CAS  PubMed  Google Scholar 

  8. Eriksson B, Kloppel G, Krenning E et al. (2008) Consensus guidelines for the management of patients with digestive neuroendocrine tumors—well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 87(1): 8–19

    Article  CAS  PubMed  Google Scholar 

  9. Modlin M, Pavel M, Kidd M, Gustadsson BI (2010) Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 31(2): 169–188

    CAS  PubMed  Google Scholar 

  10. Steinmuller T, Kianmanesh R, Falconi M et al. (2008) Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: Foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 87(1): 47–62

    Article  PubMed  Google Scholar 

  11. Kwekkeboom DJ, de Herder WW, van Eijck CHJ, Kam BL, van Essen M, Teunissen JJM, Krenning EP (2010) Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 40(2): 78–88

    Article  PubMed  Google Scholar 

  12. Halfdanarson TR et al. (2008) Pancreatic neuroendocrine tumors (PNETs): Incidence, prognosis and recent trend toward improved survival. Ann Oncol 19(10): 1727–1733

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Zhuge Y et al. (2009) Pediatric intestinal foregut and small bowel solid tumors: A review of 105 cases. J Surg Res 156(1): 95–102

    Article  PubMed  Google Scholar 

  14. Rufini V, Calcagni ML, Baum RP (2006) Imaging of neuroendocrine tumors. Semin Nucl Med 36(3): 228–247

    Article  PubMed  Google Scholar 

  15. Machens A. et al. (2007) Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): A multicentre study of 258 gene carriers. Clin Endocrinol (Oxf) 67(4): 613–622

    Google Scholar 

  16. Marini F et al. (2006) Multiple endocrine neoplasia type 1. Orphanet J Rare Dis 1: 38

    Article  PubMed  PubMed Central  Google Scholar 

  17. Pieterman CR et al. (2009) Multiple endocrine neoplasia type 1 (MEN1): Its manifestations and effect of genetic screening on clinical outcome. Clin Endocrinol (Oxf) 70(4): 575–581

    Article  CAS  Google Scholar 

  18. Tessonnier L, Sebag F, Ghander C et al. (2010) Limited value of 18F-F-DOPA PET to localize pancreatic insulin-secreting tumors in adults with hyperinsulinemic hypoglycemia. J Clin Endocrinol Metab 95(1): 303–307

    Article  CAS  PubMed  Google Scholar 

  19. Kapoor RR et al. (2009) Hyperinsulinaemic hypoglycaemia. Arch Dis Child 94(6): 450–457

    Article  CAS  PubMed  Google Scholar 

  20. Hussain K et al. (2007) Hyperinsulinaemic hypoglycaemia: Biochemical basis and the importance of maintaining normoglycaemia during management. Arch Dis Child 92(7): 568–570

    Article  PubMed  PubMed Central  Google Scholar 

  21. Hussain K (2007) Insights in congenital hyperinsulinism. Endocr Dev 11: 106–121

    Article  CAS  PubMed  Google Scholar 

  22. Pieterman CR et al. (2009) Multiple endocrine neoplasia type 1 (MEN1): Its manifestations and effect of genetic screening on clinical outcome. Clin Endocrinol (Oxf) 70(4): 575–581

    Article  CAS  Google Scholar 

  23. Kuijpers SC, Noordam C, Boelen C, Wijnen R (2004) Congenital hyperinsulinism in 15 infants, 1981–1999; experiences and new insights. Ned Tijdschr Geneeskd 148(3): 140–143

    CAS  PubMed  Google Scholar 

  24. Meissner T et al. (2003) Long-term follow-up of 114 patients with congenital hyperinsulinism. Eur J Endocrinol 149(1): 43–51

    Article  CAS  PubMed  Google Scholar 

  25. Kapoor RR, James C, Hussain K (2009) Advances in the diagnosis and management of hyperinsulinemic hypoglycemia. Nat Clin Pract Endocrinol Metab 5(2): 101–112

    Article  CAS  PubMed  Google Scholar 

  26. James C et al. (2009) The genetic basis of congenital hyperinsulinism. J Med Genet 46(5): 289–299

    Article  CAS  PubMed  Google Scholar 

  27. De Leon DD, Stanley CA (2007) Mechanisms of disease: advances in diagnosis and treatment of hyperinsulinism in neonates. Nat Clin Pract Endocrinol Metab 3(1): 57–68

    Article  PubMed  Google Scholar 

  28. Giurgea I et al. (2006) The Knudson’s two-hit model and timing of somatic mutation may account for the phenotypic diversity of focal congenital hyperinsulinism. J Clin Endocrinol Metab 91(10): 4118–4123

    Article  CAS  PubMed  Google Scholar 

  29. Suchi M, MacMullen CM, Thornton PS et al. (2006) Molecular and immunohistochemical analyses of the focal form of congenital hyperinsulinism. Mod Pathol 19(1): 122–129

    Article  CAS  PubMed  Google Scholar 

  30. Sempoux C et al. (2004) Focal and diffuse forms of congenital hyperinsulinism: The keys for differential diagnosis. Endocr Pathol 15(3): 241–246

    Article  PubMed  Google Scholar 

  31. Capito C et al. (2009) Value of 18F-fluoro-L-dopa PET in the preoperative localization of focal lesions in congenital hyperinsulinism. Radiology 253(1): 216–222

    Article  PubMed  Google Scholar 

  32. Mohnike K et al. (2008) [18F]-DOPA positron emission tomography for preoperative localization in congenital hyperinsulinism. Horm Res 70(2): 65–72

    Article  CAS  PubMed  Google Scholar 

  33. Barthlen W et al. (2008) Evaluation of [18F]fluoro-L-DOPA positron emission tomography-computed tomography for surgery in focal congenital hyperinsulinism. J Clin Endocrinol Metab 93(3): 869–875

    Article  CAS  PubMed  Google Scholar 

  34. Kapoor RR, Gilbert C, Mohnike K, Blankenstein O et al. (2008) Congenital hyperinsulinism: [18F]DOPA PET/CT scan of a focal lesion in the head of the pancreas. Arch Dis Child Fetal Neonatal Ed 93(2): F166

    Google Scholar 

  35. Ribeiro MJ, Boddaert N et al. (2007) The added value of [18F] fluoro-L-DOPA PET in the diagnosis of hyperinsulinism of infancy: A retrospective study involving 49 children. Eur J Nucl Med Mol Imaging 34(12): 2120–2128

    Article  CAS  PubMed  Google Scholar 

  36. Ribeiro MJ, Boddaert N et al. (2007) Functional imaging of the pancreas: The role of [18F]fluoro-L-DOPA PET in the diagnosis of hyperinsulinism of infancy. Endocr Dev 12: 55–66

    Article  PubMed  Google Scholar 

  37. Mohnike K, Blankenstein O et al. (2006) Proposal for a standardized protocol for 18F-DOPA-PET (PET/CT) in congenital hyperinsulinism. Horm Res 66(1): 40–42

    CAS  PubMed  Google Scholar 

  38. Otonkoski T et al. (2006) Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-DOPA positron emission tomography. Diabetes 55(1): 13–18

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pädiatrische Endokrinologie, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum (CVK), Augustenburger Platz 1, 13353, Berlin

    Dr. med. Oliver Blankenstein

  2. Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charité – Universitätsmedizin Berlin Campus Virchow-Klinikum (CVK), Augustenburger Platz 1, 13353, Berlin

    Prof. Dr. med. Marianne Pavel

Authors
  1. Dr. med. Oliver Blankenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Marianne Pavel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Diagnostisch Therapeutisches Zentrum, Berlin, Deutschland

    Wolfgang Mohnike

  2. Königstein, Deutschland

    Gustav Hör

  3. Klinikum für Nuklearmedizin, Klinikum Fulda, Fulda, Deutschland

    Andreas Hertel

  4. UCLA Molecular & Medical Pharmacology, Los Angeles, CA, USA

    Heinrich Schelbert

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Blankenstein, O., Pavel, M. (2016). Neuroendokrine Tumoren. In: Mohnike, W., Hör, G., Hertel, A., Schelbert, H. (eds) PET/CT-Atlas. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-48842-3_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-48842-3_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-48841-6

  • Online ISBN: 978-3-662-48842-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation